Ontology highlight
ABSTRACT:
Hypothesis: We thought that HPSD might bring more clinical benefits. The aim of this meta-analysis was to evaluate the clinical benefits of HPSD in patients with AF.
Methods: The Medline, PubMed, Embase, and the Cochrane Library databases were searched for studies comparing HPSD and LPLD ablation.
Results: Ten trials with 2467 patients were included in the analysis. Pooled analyses demonstrated that HPSD showed a benefit of first-pass pulmonary vein isolation (PVI) (risk ratio [RR]: 1.20; 95% confidence interval [CI]: 1.10-1.31, P?
Conclusions: HPSD was safe and efficient for treating AF. Compared with LPLD, HPSD was associated with advantages of procedural features, higher first-pass PVI and reducing recurrence of atrial arrhythmias. Moreover, major complications and ETI were similar between two groups.
SUBMITTER: Chen CF
PROVIDER: S-EPMC7724222 | biostudies-literature | 2020 Dec
REPOSITORIES: biostudies-literature
Chen Chao-Feng CF Wu Jing J Jin Chao-Lun CL Liu Mei-Jun MJ Xu Yi-Zhou YZ
Clinical cardiology 20201027 12
<h4>Background</h4>High power shorter duration (HPSD) ablation seen to increase efficacy and safety treating of atrial fibrillation (AF); however, comparative data between HPSD and low power longer duration (LPLD) ablation are limited.<h4>Hypothesis</h4>We thought that HPSD might bring more clinical benefits. The aim of this meta-analysis was to evaluate the clinical benefits of HPSD in patients with AF.<h4>Methods</h4>The Medline, PubMed, Embase, and the Cochrane Library databases were searched ...[more]